Pharmaceuticals

Targeted Alpha-Therapy Market Growth Opportunities: Insights from 2025–2029

November 21, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

How Does The Market Size Of The Targeted Alpha-Therapy Industry Compare Between 2025 And 2029?

The targeted alpha-therapy market has witnessed significant growth in recent years. Its value is projected to increase from $0.87 billion in 2024 to $1.03 billion in 2025, achieving a compound annual growth rate (CAGR) of 17.4%. This expansion historically stems from several contributing factors, such as an increase in regulatory approvals, a greater emphasis on targeted therapy compared to traditional chemotherapy, enhanced availability of alpha-emitting isotopes, a rise in both government and private funding, and a growing preference among patients for therapies that are minimally invasive.

The targeted alpha-therapy market is projected to undergo significant expansion in the coming years, with its size expected to reach $1.93 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 17.1%. This growth during the forecast period can be attributed to the increasing prevalence of cancer and metastatic diseases, the rising adoption of precision medicine, growing awareness among oncologists and patients, increasing research and development investments, and an escalating number of clinical trials. Key trends anticipated in the forecast period include advancements in radiopharmaceutical technology, technological developments in alpha-emitter production, the integration of imaging and therapy, improvements in targeted drug delivery systems, and ongoing developments in nuclear medicine technologies.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=28337&type=smp

Which Drivers Are Shaping The Targeted Alpha-Therapy Industry’s Market Share?

The increasing emphasis on precision medicine is anticipated to fuel the expansion of the targeted alpha-therapy market. Precision medicine involves a healthcare strategy that tailors prevention, diagnosis, and treatment based on an individual’s genetic makeup, lifestyle, and environment to achieve better results. This approach is gaining traction due to the expanding availability of genetic testing, which allows for more accurate diagnoses and specific treatments, leading to improved patient outcomes. Targeted alpha-therapy supports precision medicine by delivering highly potent alpha-emitting isotopes directly to cancer cells, providing personalized and precise treatment while reducing harm to healthy tissues. For instance, in March 2024, the American Pharmaceutical Review reported that global spending on precision medicine treatments was nearly $32 billion in 2022 and is expected to surpass $124 billion by 2027. Consequently, the heightened focus on precision medicine is propelling the growth of the targeted alpha-therapy market.

How Is The Targeted Alpha-Therapy Market Classified Into Different Segments?

The targeted alpha-therapy market covered in this report is segmented as

1) By Isotope Type: Actinium-225, Radium-223, Lead-212, Bismuth-213, Other Isotype Types

2) By Application: Prostate Cancer, Bone Metastases, Pancreatic Cancer, Other Applications

3) By End-User: Hospitals, Cancer Research Institutes, Specialty Clinics, Lymphoma, Other End Users

Subsegments:

1) By Actinium-225: Ac-225 Lintuzumab, Ac-225 PSMA-617, Ac-225 DOTATATE

2) By Radium-223: Radium-223 Dichloride (Xofigo)

3) By Lead-212: Pb-212 DOTAMTATE (AlphaMedix), Pb-212 TCMC-Trastuzumab

4) By Bismuth-213: Bi-213 Lintuzumab, Bi-213 DOTATOC

5) By Other Isotope Types: Thorium-227, Astatine-211, Terbium-149

How Are Emerging Market Trends Shaping The Targeted Alpha-Therapy Industry Landscape?

Leading companies in the targeted alpha-therapy market are concentrating on developing innovative solutions, such as peptide receptor radionuclide therapy, to enhance the effectiveness of targeted cancer treatment, reduce off-target effects, and improve patient outcomes. Peptide receptor radionuclide therapy (PRRT) is a targeted cancer treatment that delivers radioactive isotopes directly to tumor cells by binding them to peptides that specifically attach to receptors overexpressed on cancer cells, thereby minimizing damage to healthy tissue. For instance, in February 2024, RadioMedix Inc., a US-based biotechnology company, partnered with Orano Med, a US-based pharma company, and secured the first targeted alpha therapy to receive FDA breakthrough device designation: AlphaMedix (lead-212-Dotamtate), which targets neuroendocrine tumors. This therapy is designed to treat advanced gastroenteropancreatic neuroendocrine tumors by delivering highly potent alpha radiation directly to cancer cells while sparing healthy tissue. Its primary advantage comes from the high energy and short path length of alpha particles, which inflict lethal DNA damage on tumor cells with minimal toxicity. This therapy provides a promising option for patients who are naïve to or have shown limited response to current beta-emitter treatments, aiming to improve efficacy and safety in difficult-to-treat neuroendocrine tumors.

Who Are The Major Companies Operating In The Targeted Alpha-Therapy Market?

Major companies operating in the targeted alpha-therapy market are Bayer Aktiengesellschaft, Novartis AG, Lantheus Holdings Inc., Telix Pharmaceuticals Limited, Eckert & Ziegler Strahlen- und Medizintechnik AG, Actinium Pharmaceuticals Inc., RayzeBio Inc., ITM Isotope Technologies Munich SE, ARTBIO Inc., AdvanCell Pty Ltd., IONETIX Corporation, Abdera Therapeutics Inc., Aktis Oncology Inc., Alpha-9 Oncology Inc., Clarity Pharmaceuticals Pty Ltd., Nucleus RadioPharma, Oncoinvent AS, PanTera, Perspective Therapeutics Inc., RadioMedix Inc.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/targeted-alpha-therapy-global-market-report

What Regional Growth Trends Are Shaping The Targeted Alpha-Therapy Market Outlook?

North America was the largest region in the targeted alpha-therapy market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in targeted alpha-therapy report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Request A Customized Version Of The Targeted Alpha-Therapy Market Report:

https://www.thebusinessresearchcompany.com/customise?id=28337&type=smp

Browse Through More Reports Similar to the Global Targeted Alpha-Therapy Market 2025, By The Business Research Company

Targeted Therapy Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/targeted-therapy-global-market-report

Alpha Hydroxy Acid Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/alpha-hydroxy-acid-global-market-report

Alpha 1 Antitrypsin Deficiency Augmentation Therapy Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/alpha-1-antitrypsin-deficiency-augmentation-therapy-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795